Persian
Albanian
Arabic
Armenian
Azerbaijani
Belarusian
Bengali
Bosnian
Catalan
Czech
Danish
Deutsch
Dutch
English
Estonian
Finnish
Français
Greek
Haitian Creole
Hebrew
Hindi
Hungarian
Icelandic
Indonesian
Irish
Italian
Japanese
Korean
Latvian
Lithuanian
Macedonian
Mongolian
Norwegian
Persian
Polish
Portuguese
Romanian
Russian
Serbian
Slovak
Slovenian
Spanish
Swahili
Swedish
Turkish
Ukrainian
Vietnamese
Български
中文(简体)
中文(繁體)

The United Kingdom Multiple Sclerosis Register Covid-19 Substudy

فقط کاربران ثبت نام شده می توانند مقالات را ترجمه کنند
ورود به سیستم / ثبت نام
پیوند در کلیپ بورد ذخیره می شود
وضعیتاستخدام
حامیان مالی
Swansea University

کلید واژه ها

خلاصه

The aim of the study is to understand the impact of COVID-19 on People with Multiple Sclerosis in the United Kingdom.

شرح

Study objectives

1. To identify the incidence of upper respiratory tract symptoms: fever, cough and breathing difficulties, other symptoms suggestive of COVID-19 infection, respiratory tract infections suggestive of COVID-19, and COVID-19 confirmed by laboratory testing among the UK MS population

2. To establish if some DMDs increase the risk of COVID-19 infection

3. To determine the incidence and effectiveness of self-isolation in the MS population. To examine the impact self-isolation has on mood, fatigue, and other routinely collected patient reported outcome measures from the MS Register.

4. To determine the clinical outcome of respiratory tract infections, including confirmed and suspected cases of COVID-19, in terms of symptoms, time to recovery, hospital admission, requirement for ventilation, and death.

5. To determine the longer-term impact of COVID-19 on MS, using routinely collected MS outcomes in the MS register, including impact on disability, relapses and changes in DMDs as assessed at 3 monthly intervals.

6. To determine where people are obtaining their health information during the COVID-19 outbreak.

7. To establish changes in DMDs prior to and as a result of symptoms related and unrelated to COVID-19

تاریخ

آخرین تأیید شده: 02/29/2020
اولین ارسال: 04/05/2020
ثبت نام تخمینی ارسال شد: 04/19/2020
اولین ارسال: 04/20/2020
آخرین بروزرسانی ارسال شده: 06/18/2020
آخرین به روزرسانی ارسال شده: 06/21/2020
تاریخ شروع مطالعه واقعی: 03/13/2020
تاریخ تخمین اولیه اولیه: 07/13/2021
تاریخ برآورد مطالعه: 07/13/2022

شرایط یا بیماری

Multiple Sclerosis
COVID-19

فاز

-

گروههای بازو

بازومداخله / درمان
Confirmed Cases
Diagnosed by health professional / Covid-19 test Monitored through fortnightly questionnaires
Not Covid-19 cases
Through self report no suspicion of COVID-19, tested by fortnightly questionnaire. non Covid Cases can become COVID cases through self report.
Suspected Covid-19 Cases
Participants that are suspected of having Covid-19 but this has not been confirmed by health professional or Covid-19 test has not been performed. Fortnighly questionnaire

معیارهای صلاحیت

سنین واجد شرایط تحصیل 18 Years به 18 Years
جنسیت واجد شرایط مطالعهAll
روش نمونه گیریNon-Probability Sample
داوطلبان سالم را می پذیردآره
شاخص

Inclusion Criteria:

- >18 and confirmed diagnosis of MS, enrolled on UK MS Register

Exclusion Criteria:

- None of the above

نتیجه

اقدامات اولیه

1. Incidence of COVID-19 Infections within an MS Cohort in the UK [Through study completion, an average of 1 year]

Targeted questionnaire dependent on COVID Status

2. Hospitalisations in MS Patients with COVID-19 [1 Year (regular outputs)]

Monitor admission rates in linked population

3. Mortality [1 Year from study commencement]

Death data from routinely reported government level data (HES/PEDW)

اقدامات ثانویه

1. Patient Reported Expanded Disability Status Score [1 year (at least 6 monthly)]

Patient Reported Outcome for MS disability

2. Hospital Anxiety and Depression Scale [1 year (at least 6 monthly)]

Patient Reported Outcome for anxiety and depression

3. Multiple Sclerosis Impact Scale 29 V2 [1 year (at least 6 monthly)]

Patient Reported Outcome for Multiple sclerosis impact on physical and psychological status

4. Multiple Sclerosis Walking Scale 12 V2 [1 year (at least 6 monthly)]

Patient Reported Outcome for walking status

5. Fatigue Severity Scale [1 year (at least 6 monthly)]

Patient Reported Outcome for impact of fatigue

6. EuroQol 5D (3l) [1 year (at least 6 monthly)]

Patient Reported Outcome for general quality of life

به صفحه فیس بوک ما بپیوندید

کاملترین پایگاه داده گیاهان دارویی با پشتیبانی علمی

  • به 55 زبان کار می کند
  • درمان های گیاهی با پشتوانه علم
  • شناسایی گیاهان توسط تصویر
  • نقشه GPS تعاملی - گیاهان را در مکان نشان دهید (به زودی)
  • انتشارات علمی مربوط به جستجوی خود را بخوانید
  • گیاهان دارویی را با توجه به اثرات آنها جستجو کنید
  • علایق خود را سازماندهی کنید و با تحقیقات اخبار ، آزمایشات بالینی و حق ثبت اختراع در جریان باشید

علامت یا بیماری را تایپ کنید و در مورد گیاهانی که ممکن است به شما کمک کنند ، بخوانید ، یک گیاه تایپ کنید و بیماری ها و علائمی را که در برابر آن استفاده می شود ، ببینید.
* کلیه اطلاعات براساس تحقیقات علمی منتشر شده است

Google Play badgeApp Store badge